Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1

Interventions

Cytarabine 81Azacitidine 66venetoclax 55fludarabine 34fludarabine phosphate 31Decitabine 28Cyclophosphamide 28Idarubicin 24Peripheral Blood Stem Cell Transplantation 22Filgrastim 20Granulocyte Colony-Stimulating Factor 18Busulfan 18Mitoxantrone 16Etoposide 16Whole-Body Irradiation 15Mycophenolic Acid 14Cyclosporine 14Tacrolimus 13Melphalan 13Daunorubicin 13Clofarabine 13Methotrexate 12gilteritinib 11aldesleukin 11plerixafor 10Injections 10decitabine and cedazuridine drug combination 9Gemtuzumab 9Cladribine 9quizartinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myeloid, Acute × Antineoplastic Agents × Clear all
NCT00831766 2020-12-22

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
51 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡